US Pharma MarketingFDA criticizes Lundbeck for now-deleted webpages promoting its migraine treatment
The FDA slams Lundbeck for now-deleted Vyepti webpages claiming Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation…
The FDA has chastised Lundbeck Seattle Biopharmaceuticals for two promotional webpages, neither of which is still online, that made allegedly inflated claims regarding the efficacy of its migraine drug.
In an
Source: Endpoints News